EnClear Therapies, Inc.

Founded in 2018 and based in Massachusetts, US, EnClear Therapies, Inc. develops a device-based treatment to remove toxic protein buildup in cerebrospinal fluids that cause neurodegeneration in patients suffering from Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Progressive Supranuclear Palsy (PSP). In September 2024, EnClear Therapies, Inc. raised venture funding from the National Brain Tumor Society and The Sontag Foundation, including Amgen Ventures, Founders Fund, Thiel Bio, Tachyon Ventures, and Bioverge.

As of 2024, the company is led by its CEO and president, Tony DePasqua. The company specializes in addressing the challenge of delivering therapeutics across barriers like the blood-brain barrier (BBB), blood-cSF, and blood-arachnoid barriers. The firm’s core technology, the EnTrega CSF Platform, is designed to deliver therapeutics to targeted areas within the CNS through the cerebrospinal fluid (CSF). This method allows for controlled, continuous, and personalized delivery, which optimizes dosage, increases therapeutic efficacy, and minimizes the risk of peripheral toxicity and severe side effects.

In addition, the company’s platform facilitates easy access to CSF for monitoring and diagnostics. The firm’s partners include Amgen, Thiel, Quark Venture, Sanford Biosciences, Bioverge, and others. The organization plans to use the September 2024 funding to accelerate the development of its novel technology in neuro-oncology.